Najaf Ali Soomro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Najaf Ali Soomro has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Hao Liang
State Key Laboratory of Chemical Resource Engineering Beijing University of Chemical Technology Beijing P. R. China
1 shared publication - Khalid Hussain Thebo
Department of Chemistry, Mirpur University of Science and Technology, Mirpur Azad, Jammu and Kashmir, Pakistan
1 shared publication - Mohsin Kazi
Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia
1 shared publication - Muhammad Tariq
College of Life Science and Technology, and State Key Laboratory of Chemical Resource Engineering Beijing University of Chemical Technology Beijing China
1 shared publication - Quratulain Khuhro
Institute of Biochemistry University of Sindh Jamshoro Pakistan
1 shared publication - Safdar Ali Amur
Department of Chemistry, Faculty of Natural Science, Government College University, Hyderabad, 71000, Sindh, Pakistan
1 shared publication
Latest Publications
- 22 May 2025
- Published by Wiley in Applied Organometallic Chemistry
- Vol. 39 (6)
Green Synthesis of Glabridin‐Loaded Zeolitic Imidazolate Framework‐8 Drug Delivery System: Characterization, Synergistic Antibacterial Efficacy, and pH‐Dependent Drug Release Kinetics
This study reports a green one‐pot synthesis of glabridin‐loaded Zeolitic Imidazolate Framework‐8 (Glab@ZIF‐8) drug delivery system (DDS) with exceptional drug loading encapsulation (DLE) of ≈ 98.7% and drug loading capacity (DLC) of 32%, surpassing values reported in previous ZIF‐8‐based DDS. Characterizations using Fourier‐transform infrared (FTIR), UV–Visible spectroscopy, dynamic light scattering (DLS), and X‐ray diffraction (XRD) confirmed successful encapsulation of Glab within ZIF‐8 while preserving its crystallinity. Glab@ZIF‐8 exhibited a hexagonal morphology with increased particle size (138.6 ± 5.4 nm) and a higher zeta potential (+41.9 mV), suggesting enhanced colloidal stability and efficient drug entrapment. Thermogravimetric analysis (TGA) demonstrated a total of 32.1% decomposition of Glab@ZIF‐8 up to 644 °C. Antibacterial assays revealed that Glab@ZIF‐8 exhibited superior activity against Staphylococcus aureus (inhibition zone: 26.2 ± 0.3 mm) and Escherichia coli (23.3 ± 0.2), comparable to that of ampicillin. The minimum inhibitory concentration (MIC) was determined to be 32.5 μg/100 μL. Furthermore, the time‐kill studies confirmed a dose‐ and time‐dependent antibacterial effects of Glab@ZIF‐8. In vitro drug release studies showed strong pH‐ and temperature‐responsive behavior, with a cumulative release of 93.7% ± 2.4% release at pH 5 (at 37°C) over 72 h. The Glab@ZIF‐8 system thus combines high drug loading efficiency, excellent antibacterial activity, and tuneable release characteristics, highlighting its potential as a promising DDS for combating drug‐resistant infections.
- 22 May 2025
- Published by Wiley in Applied Organometallic Chemistry
- Vol. 39 (6)
Green Synthesis of Glabridin‐Loaded Zeolitic Imidazolate Framework‐8 Drug Delivery System: Characterization, Synergistic Antibacterial Efficacy, and pH‐Dependent Drug Release Kinetics
This study reports a green one‐pot synthesis of glabridin‐loaded Zeolitic Imidazolate Framework‐8 (Glab@ZIF‐8) drug delivery system (DDS) with exceptional drug loading encapsulation (DLE) of ≈ 98.7% and drug loading capacity (DLC) of 32%, surpassing values reported in previous ZIF‐8‐based DDS. Characterizations using Fourier‐transform infrared (FTIR), UV–Visible spectroscopy, dynamic light scattering (DLS), and X‐ray diffraction (XRD) confirmed successful encapsulation of Glab within ZIF‐8 while preserving its crystallinity. Glab@ZIF‐8 exhibited a hexagonal morphology with increased particle size (138.6 ± 5.4 nm) and a higher zeta potential (+41.9 mV), suggesting enhanced colloidal stability and efficient drug entrapment. Thermogravimetric analysis (TGA) demonstrated a total of 32.1% decomposition of Glab@ZIF‐8 up to 644 °C. Antibacterial assays revealed that Glab@ZIF‐8 exhibited superior activity against Staphylococcus aureus (inhibition zone: 26.2 ± 0.3 mm) and Escherichia coli (23.3 ± 0.2), comparable to that of ampicillin. The minimum inhibitory concentration (MIC) was determined to be 32.5 μg/100 μL. Furthermore, the time‐kill studies confirmed a dose‐ and time‐dependent antibacterial effects of Glab@ZIF‐8. In vitro drug release studies showed strong pH‐ and temperature‐responsive behavior, with a cumulative release of 93.7% ± 2.4% release at pH 5 (at 37°C) over 72 h. The Glab@ZIF‐8 system thus combines high drug loading efficiency, excellent antibacterial activity, and tuneable release characteristics, highlighting its potential as a promising DDS for combating drug‐resistant infections.